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1. introduction 
Several nuclease inhibitors of a protein nature have 
been found in animal cells [l-4] in the soluble fraction 
of the cytoplasm. There has been no direct indication 
of the presence of such inhibitors in the nucleus. 
While studying the RNase activity of purified his- 
tones isolated from rat liver and hepatoma cells (to be 
reported in due course) we sometimes observed partial 
or even complete inhibition of this activity which could 
be released by treatment of histone preparations with 
p-chlormercuribenzoate (p-CMB). It was possible to 
avoid inhibition of RNase activity only when an ex- 
haustive extraction of nuclear sap from the nuclei was 
carried out before isolation of histones. The above ob- 
servation suggested that a potent RNase inhibitor of a 
protein nature, sensitive to p-CMB, might be present in 
the nuclear sap. This paper describes the purification and 
some properties of the nuclease inhibitor from the nu- 
clear sap. 
2. Materials and methods 
Nuclei were isolated from the liver of rats (140- 
200 g) by the modified method of Chauveau [5]. The 
liver was washed to remove blood, minced in the cold, 
forced through a French press and homogenized in a 
glass homogenizer with a teflon pestle (500-800 rpm, 
4-5 strokes) in 0.88 M sucrose-l .5 mM CaCl,,--0.05 
M tris-HCl, pH 7.4. The filtrate was layered on a suc- 
rose solution (d = 1.268) containing 0.5 mM CaClz 
and centrifuged at 60,000 g for 90 min (Spinco L-2, 
North-Holland Publishing Company - Amsterdam 
# 30). For additional purification of the nuclei, the 
procedure was repeated twice. The nuclear preparations 
were examined microscopically (stained with toluidine 
blue) and were characterized by their content of RNA 
and DNA (P-DNA, 7.0 pg; P-RNA, 2.0 pg). 
For isolation of nuclei from Zajdela hepatoma, the 
cell suspension was centrifuged at 200 rpm for 10 min; 
to remove erythrocytes, the cells were suspended in 
0.14 M NaCl (pH 7.2) and recovered by centrifuga- 
tion at 600 g for 3 min. The washed cells were sub- 
jected to an osmotic shock and homogenized in 0.25 M 
sucrose-O.025 M KCl-0.0015 M CaCl*-0.05 M tris- 
HCl buffer pH 7.4. The homogenate was layered on a 
0.88 M sucrose-O.05 M tris buffer pH 7.4 and the 
nuclei sedimented at 20,000 g for 15 min. The pro- 
cedure was repeated once more. 
The nuclear sap from the liver and hepatoma nuclei 
was removed repeatedly with 0.14 M NaCl-0.001 M 
MgClz pH 7.2 at 3-4’ until no protein was detectable 
in the extract. 
Nuclear ribosomes were removed from the sap by 
centrifugation at 190,000 g (# 50) for 2 hr. 
3. Results 
In the ribosome-free nuclear sap only proteins with 
solubility properties characteristic of globulins (pre- 
cipitating with ammonium sulfate at 0.35-0.7 satura- 
tion) were found to possess inhibitory activity as re- 
vealed in experiments with various RNases (for ex- 
perimental conditions see legend to tables 1 and 3). 
The albumins from the nuclear sap showed no activity 
(table 1). 
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Table 1 
Inhibitory activity of protein fractions from the nuclear sap. 
Additions Pancreatic 
RNase activity* 
Inhibitor 
units** 
Pancreatic 
RNase activity 
in the presence 
pCMB 
_ 0.80 0’ _ 
a) Nuclear sap 0.40 1.3 0.85 
b) Globulins 0.03 29 0.89 
c) Albumins 1.035 0 - 
d) Residue*** 0.84 0 _ 
* Expressed as an increase in the absorbance at 260 nm of the acid soluble fraction of the incubation mixture. 
** Inhibitory unit: 50% inhibition of the activity of 0.05 pg pancreatic RNase. 
*** Left after the extraction of globulins and the bulk of albumins from the total protein precipitated by ammonium sulfate 1.0 
saturation. 
Incubation conditions: total volume of the sample 3 ml; RNase 0.15 mg; rat liver ribosomal RNA 1.5 mg; a) 746 pg; b) 62 pg; 
c) 600 ~g; d) 130 pg; incubation time 1 hr at 37’. The assay was performed in 0.05 M tris-HCl containing 0.1 M NaCl. 
Table 2 
Inactivation of the inhibitors by different factors. 
Residual activity of the inhibitor 
in % 
Test enzyme Treatment of 
the inhibitor 
Cytoplasmic Globulin 
fraction of 
the nuclear 
SaP 
Pancreatic RNase Heating (60”, 82 100 
0.05 pg 5 min) pH 6.8 
0.25 N HzS04 0 0 
(60 min) 
cu2+ (10 /.JM) 71 91 
Pancreatic DNase Heating (60°, 0 94 
0.15 /bg 5 min) pH 6.8 
0.25 N HzS04 0 0 
(60 min) 
Some properties of the nuclear inhibitor and cyto- 
plasmic RNase inhibitor (the latter was isolated by the 
method of Roth [ 1 I) were compared. As can be seen 
from table 2, both nuclear and cytoplasmic inhibitors 
can act not only on RNases but also on DNases (their 
inhibitory activities were tested by the effect on pan- 
creatic RNase and DNase, separately). 
The nuclear inhibitor is more resistant than the 
cytoplasmic one to heating and action of the heavy 
bivalent cations (table 2). There is also dissimilarity in 
their effects on different nuclease (table 3). Of the two 
inhibitors studied, the nuclear one proved to be more 
efficient especially towards histone and chromatin 
acidic protein RNase activities. 
Preparations of nuclear and cytoplasmic inhibitors 
were then subjected to successive chromatography on 
the hydroxyapatite [4] and DEAE-Sephadex columns, 
which allowed us to purify the nuclear inhibitor 
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Fig. 1. DEAE-Sephadex A-50 chromatography. Column 1 X 15 cm. Flow rate 20 ml per hr. Stepwise elution with NaCl solution 
containing 0.02 M tris-HCl buffer pH 7.4. Fractions (3 ml each) were collected by the automatic collector (LKB). Amount of pro- 
tein in the fractions was determined (after dialysis) by the Lowry’s method [lo]. Activity of the inhibitor was measured as its ef- 
fect on the pancreatic RNase in 0.05 M tris-HCI buffer pH 7.6 containing 0.1 M NaCl (incubation at 37O for 1 hr) and expressed in 
inhibitory units (see the legend to table l), striped columns. - - - - - - original level of the inhibitor effect. (A) Cytoplasmic inhibitor; 
(B) Nuclear sap. 
Fig. 2. Reciprocals of the substrate concentration in pg (l/S) 
plotted against he reciprocal of the reaction rate expressed as 
A2eo (l/v) of the acid soluble fraction of the incubation mix- 
ture. Composition of the incubation mixture: calf thymus DNA, 
ribosomal DNase, globulin inhibitor from the nuclear sap. Time 
of incubation 30 min at 37O. (1) Ribosomal DNase; (II) ribosomal 
DNase + inhibitor. 
2,000-fold compared with the original sap. These pro- 
cedures revealed one more substantial difference be- 
tween the two inhibitors: the cytoplasmic inhibitor 
was eluted from the DEAE-Sephadex column as a sin- 
gle peak whereas the nuclear one appeared in several 
protein fractions on the DEAE-Sephadex chromato- 
graphy (fig. l), all of which possess inhibitory activ- 
ity towards both RNases and DNases. 
The results of special experiments expressed accord- 
ing to the equation of Lineweaver and Burk provided 
evidence that the relationships between both pancreatic 
DNase and RNase and the nuclear inhibitor are of a 
competitive character (fig. 2). 
The data presented in this paper reveal the presence 
in the liver and hepatoma nuclear sap of a potent 
RNase and DNase inhibitor. Its activity is confined 
to the globulin fraction only. This nuclear inhibitor 
differs in some properties from the previously known 
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Table 3 
Effect of the inhibitors on different enzymes (% of inhibition). 
Nuclease 
Inhibitors 
Cy toplasmic Globulin fraction of nuclear cell sap 
Liver Hepatoma Liver Hepatoma 
RNase 
1) Bovine pancreatic 
2) Rat liver acidic [6] 
3) Guanylic (actino- 
mycetes) [ 71 
4) Acidic protein of 
the nuclear nucleo- 
protein (rat liver) [ 81 
5) Ribosomal (rat liver) 
6) Histones (rat liver) 
70 90 48 94 
0 _ 0 0 
0 - 0 0 
50 _ 82 98 
66 30 50 50 
52 65 100 100 
DNase 
Bovine pancreatic 
Ribosomal (rat liver) 
Ribosomal (rat hepa- 
toma) 
98 94 100 100 
80 50 90 100 
72 80 94 96 
Incubation mixture (3 ml) for all of the RNases contained rat liver ribosomal RNA (1.5 mg) as substrate and a) tris-HCl buffer 
0.05 M pH 8-NaClO.1 M (for the RNases with alkaline pH optimum) or b) acetic buffer 0.02 M pH 5.6 (for acidic RNase). Incu- 
bation 1 hr at 37O. 
The amounts of the given enzymic activity (in E units) were equal in the experiments in which the action of different inhibitors 
on the same enzyme were compared for a) acidic RNase 3, b) guanylic 10, c) acidic protein of chromatin 0.82, d) ribosoma18, 
e) histones 1.0. The enzyme unit: amount of the protein bringing about an increase in the absorbance (Aseo) of the acid soluble 
fraction by 1 A within 60 min incubation. Pancreatic RNase 0.02 pg. 
Content of inhibitors in pg protein: a) rat liver nuclei 246, b) hepatoma nuclei 306, c) rat liver cytoplasm 264. 
Incubation mixture (3 ml) for all of the DNases contained 600 r.ig rat liver DNA. Time of incubation 2 hr at 37’. a) Pancreatic 
DNase: enzyme 0.15 pg, MgClz 5 mM, tris-HCl buffer 0.05 M pH 7.6, NaClO.1 M, b) rat liver ribosomal DNase: enzyme 2.5 units, 
MgClz 5 mM, tris-HCI 0.05 M pH 8.1, NaCl 0.1 M, c) hepatoma ribosomal DNase: enzyme 2.27 units, MgCla 5 mM, tris-HCl buffer 
pH 8.1. Content of inhibitors in pg protein from: a) rat liver nuclei 560, b) hepatoma nuclei 600, c) rat liver cytoplasma 650. 
cytoplasmic RNase inhibitor. It is possible that our 
inhibitor is the one whose presence in the “bound” 
form of nuclear RNase might be suggested from the 
experiments of Busch et al. [9]. 
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